| |
| |
|
| Insider
Information: |
Lewis Tanya |
| Relationship: |
Chief Dev. Op. Officer |
| City: |
New Haven |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
200,694 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$936,555 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
200,694 |
|
|
| Total
Value |
$936,555 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -66.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vion Pharmaceuticals Inc |
VIONQ |
VP Regulatory and Qual... |
2008-12-10 |
20,000 |
2008-12-10 |
0 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
EVP, Chief Reg. Affairs |
2021-02-25 |
45,401 |
2020-10-28 |
0 |
Premium* |
|
|
Replimune Group Inc |
REPL |
Chief Dev. Op. Officer |
2023-06-13 |
135,293 |
2021-05-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
11 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REPL |
Replimune Group Inc |
Chief Dev. Op. Officer |
• – – |
2023-06-13 |
4 |
AS |
$23.45 |
$309,395 |
D/D |
(12,860) |
135,293 |
0 |
% |
|
| REPL |
Replimune Group Inc |
Chief Dev. Op. Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$220,336 |
D/D |
(12,207) |
148,153 |
0 |
% |
|
| REPL |
Replimune Group Inc |
Chief Dev. Op Officer |
• – – |
2022-05-16 |
4 |
S |
$14.59 |
$79,851 |
D/D |
(5,473) |
120,360 |
0 |
% |
|
| REPL |
Replimune Group Inc |
Chief Dev.Op Off |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
125,833 |
0 |
- |
|
| REPL |
Replimune Group Inc |
Chief Dev. Oper. Off. |
• – – |
2021-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
73,333 |
73,333 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
EVP, Chief Reg. Affairs |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
22,013 |
45,401 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
EVP, Chief Reg. Affairs |
• – – |
2021-02-11 |
4 |
S |
$15.52 |
$31,752 |
D/D |
(2,046) |
4,143 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
EVP, Chief Reg. Affairs |
• – – |
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,650 |
6,189 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
EVP,Chief Reg.&Quality Officer |
• – – |
2020-10-30 |
4 |
S |
$15.58 |
$3,521 |
D/D |
(226) |
539 |
0 |
% |
|
| KPTI |
Karyopharm Therapeutics I... |
EVP,Chief Reg.&Quality Officer |
• – – |
2020-10-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
765 |
765 |
0 |
- |
|
| VIONQ |
Vion Pharmaceuticals Inc |
VP Regulatory and Quality |
• – – |
2008-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
0 |
- |
|
11 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
